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What Can Current Stimulation Tell Us about the
Vascular Function of Endogenous Prostacyclin
in Healthy Rat Skin In Vivo?
Ste´phanie Gohin1, Dominique Sigaudo-Roussel1, Agne`s Conjard-Duplany2, Laurence Dubourg2, Jean Louis
Saumet1 and Be´renge`re Fromy1
In endothelial function, prostacyclin (PGI2) is as important as nitric oxide (NO); however, no test assesses
specifically the vascular function of endogenous PGI2. We hypothesized that PGI2 has a dominant role in
cathodal current-induced vasodilation (CIV) described in human skin. We thus aimed to study, in physiological
conditions, the PGI2 involvement in cathodal CIV in rats in order to use pharmacological blockers that could not
be used in humans. CIV was reduced by cyclooxygenase (COX)-1 and PGI2 synthase (PGIS) and PGI2 receptor
(IP) blockers, but was unchanged by COX-2 and NO synthase (NOS) blockers. The level of 6-ketoPGF1a present
in skin biopsies, measured as endogenous PGI2, was increased by cathodal current stimulation, except under
COX-1 and PGIS inhibition. This study provides evidence that cathodal CIV mainly relies on the release of PGI2
endogenously produced through the COX-1/PGIS pathway, and then acts on IP receptors to relax the cutaneous
microvessels in healthy rats. In contrast, neither COX-2 nor NOS is involved in CIV and the endogenous PGI2
release by current stimulation. This finding shows that cathodal current stimulation could be a valuable method
to assess the vascular function of endogenous PGI2 in healthy skin.
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INTRODUCTION
Prostacyclin (PGI2), the major cyclooxygenase (COX) product
of arachidonic acid in the vascular endothelium, is a strong
vasodilator on vascular beds (Funk, 2001; Fitzgerald, 2004)
and acts as an inhibitor of platelet aggregation, a conclusion
supported by an increase in thrombosis tendency in PGI2
receptor (IP) knockout mice (Murata et al., 1997; Cheng et al.,
2002). In contrast, thromboxane A2 (TxA2), the predominant
COX product of arachidonic acid in platelets, is a potent
vasoconstrictor and platelet agonist. At the skin level, it
has been postulated that progressive ischemic necrosis is
secondary to excessive TxA2 production, which upsets the
normal PGI2/TxA2 balance (Robson et al., 1980; Ozyazgan
et al., 1998). PGI2 analogs (such as iloprost) are thus used to
maintain the normal balance between PGI2 and TxA2 in
reconstructive surgery in order to improve the skin flap
survival (Edstrom et al., 1988; Akan et al., 2005), as well as in
Raynaud’s patients with scleroderma to decrease the freq-
uency and severity of attacks (Hachulla et al., 2008). Indeed,
in almost every patient with systemic sclerosis affecting the
skin and other organs, microvascular damage attributed to
endothelial dysfunction is one of its first pathological changes
(Sgonc et al., 1996; Marie and Beny, 2002; Maurer et al.,
2009). Besides other unclear mechanisms (Knock et al.,
1993), an inability of endothelial cells to synthesize or release
PGI2 (Rustin et al., 1987) and an increased biosynthesis of
thromboxane are thus reported in patients with systemic
sclerosis (Reilly et al., 1986). Therefore, in the diagnosis of
endothelial dysfunction, assessing the vascular function of
endogenous PGI2 in healthy skin is as important as the
vascular function of endogenous nitric oxide (NO) that could
be tested by the acetylcholine (ACh)-induced vasodilation.
However, testing the vascular function of PGI2 endogen-
ously produced by healthy skin has never been reported.
Antiplatelet aggregation assays provide an important method
to test the antithrombotic benefits of PGI2 and the vascular
responses to arachidonic acid and/or PGI2 analogs provide a
measure of the efficiency of the downstream pathways.
Urinary 6-ketoPGF1a measurements represent a highly
specific, non-invasive index of endogenous PGI2 biosynth-
esis. However, these urinary measurements predominantly
reflect renal PGI2 generation under physiological conditions
(Patrono et al., 1982) rather than systemic biosynthesis. A
large cutaneous production of endogenous PGI2 can be
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evaluated by measuring 6-ketoPGF1a levels in the skin as
reported in mice in response to mechanical scratching
inducing skin damage (Sugimoto et al., 2006).
We and others previously demonstrated in humans a
significant increase in cutaneous blood flow in response to
non-noxious galvanic current application (Grossmann et al.,
1995; Durand et al., 2002b), as observed after transcutaneous
electrical nerve stimulation (Westerman et al., 1987). This
current-induced vasodilation (CIV) is sensitive to aspirin and
indomethacin, non-specific inhibitors of COX (Durand et al.,
2002a; Tartas et al., 2005b) but not sensitive to celecoxib, a
specific COX-2 inhibitor (Tartas et al., 2005a), suggesting a
role for COX-1. The COX enzyme forms the prostaglandin
endoperoxide, prostaglandin H synthase 2, which is then
predominantly transformed into PGI2 by PGI2 synthase (PGIS)
in blood vessels (Wu, 1995; Smith et al., 1996). These
observations strongly suggest that PGI2 has a dominant role in
this cutaneous CIV and would thus represent a model easily
accessible and attractive for human studies to assess the
vascular function of endogenous PGI2 at the skin level.
Testing the overall health of the microvasculature in the skin
is not restricted to prevent the cutaneous disorders that upset
the normal PGI2/TxA2 balance. Indeed, the cutaneous
microvascular function provides an opportunity to study
non-invasively the in-depth microvascular function (Holowatz
et al., 2008). Accordingly, microvascular abnormalities
demonstrable in the skin microcirculation have been reported
in subjects with an increased risk of coronary heart disease
(IJzerman et al., 2003).
Representing a useful model easily accessible and
attractive for human studies, we first aimed to define
precisely the underlying mechanisms involved in cathodal
CIV in physiological conditions. In this context, we studied
the specific involvement of endogenous PGI2 in cutaneous
CIV and its underlying pathway in healthy rats, which
provided the opportunity to use pharmacological blockers
that could not be used in humans. We also studied
the role of NO in cathodal CIV, a role that has not been
explored previously. To assess the relevance of galvanic
stimulation to ACh stimulation in physiologic studies in
skin, we also studied the involvement of NO synthase
(NOS) and COX pathways in the cutaneous ACh-mediated
vasodilation.
RESULTS
The treatments did not change the basal cutaneous blood
flow (31.3±3.6 arbitrary unit), the cutaneous temperature
(35.62±0.02 1C) or the systolic arterial blood pressure
(92±5mmHg), except the NG-nitro-L-arginine (LNNA) treat-
ment that induced an increase of 49±10% in the systolic
arterial blood pressure, showing the efficiency of the NOS
inhibition.
COX/PGIS/IP involvement in cathodal CIV
Cathodal stimulation increased cutaneous blood flow in the
45% DMSO control rats, corresponding to a percent increase
over the baseline of 72±10%. This cathodal CIV was
reduced by COX-1/2 inhibition with aspirin (14±4%,
Po0.01), COX-1 inhibition with SC560 (17±8%, Po0.01),
and IP blockade with CAY10441 (16±4%, Po0.01) but
unchanged by COX-2 inhibition with SC58125 (62±13%)
(Figures 1a, b and 2).
CIV was reduced by PGIS inhibition with U-51605
(19±4%, Po0.001) compared with 6% methylacetate
control rats (73±12%) (Figures 1c and 2).
NOS involvement in cathodal CIV
CIV was unchanged by NOS inhibition with LNNA
(88±18%) but abolished by the dual inhibition of COX and
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Figure 1. COX/PGIS/IP involvement in cathodal CIV. Time course of
cutaneous blood flow in response to cathodal current stimulation (240 seconds,
100mA indicated by hatched area) in 45% DMSO control rats (n¼10) and rats
receiving COX inhibitor (aspirin, n¼10) (a). Mean±SEM of CIV in response to
cathodal current stimulation (240 seconds, 100mA) in 45% DMSO control rats
(n¼ 10) and rats receiving COX inhibitor (aspirin, n¼ 10), COX-1 inhibitor
(SC560, n¼10), COX-2 inhibitor (SC58125, n¼ 10), IP receptor antagonist
(CAY10441, n¼10) (b); 6% MA control rats (n¼ 10) and rats receiving PGIS
inhibitor (U-51605, n¼ 10) (c); saline control rats (n¼10) and rats receiving
NOS inhibitor (NG-nitro-L-arginine, n¼ 10) and combined COX and NOS
inhibitors (n¼ 5; d). *Po0.05, **Po0.01, ***Po0.001 versus respective
controls. a.u., arbitrary units; C, control rat, CIV, current-induced vasodilation;
COX, cyclooxygenase; IP, prostacyclin receptor; MA, methylacetate; NOS,
nitric oxide synthase; PGIS, prostacyclin synthase.
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NOS with LNNA in presence of aspirin (aspirinþ LNNA,
4±4%, Po0.05) compared with saline control rats
(78±16%) (Figure 1d).
Measurements of 6-ketoPGF1a levels
Cathodal current stimulation (240 seconds, 100 mA) increased
6-ketoPGF1a levels from 481±50 pgml
1 at baseline to
1,217±146pgml1 (Po0.001, Figures 2 and 3) at the stimu-
lated site, representing a percent increase from baseline
of 153% in untreated rats. Current stimulation similarly
increased 6-ketoPGF1a levels under COX-2 inhibition with
SC58125 (1,560±194pgml1, Po0.001 from baseline,
Figure 3) and NOS inhibition with LNNA (1,268±67pgml1,
Po0.001 from baseline, Figure 3). In contrast, current
stimulation did not increase 6-ketoPGF1a levels under COX
inhibition with aspirin (153±9pgml1), COX-1 inhibition with
SC560 (144±16pgml1), and PGIS inhibition with U-51605
(188±13pgml1, Figure 3).
The injection of arachidonic acid strongly increased
6-ketoPGF1a levels to 2,187±82 pgml
1 (Po0.001 from
baseline) in untreated rats, representing an increase of 355%.
NOS and COX involvement in the ACh-mediated vasodilation
The iontophoretic delivery of ACh in the skin increased the
cutaneous blood flow from baseline in the untreated control
rats, corresponding to a vasodilation of 70±7% (Figure 4).
This ACh-mediated vasodilation was reduced by LNNA
(15±6%, Po0.001) and by aspirinþ LNNA (9±1%,
Po0.001) compared with untreated rats, but was unchanged
by aspirin (69±6%), SC560 (61±13%) and SC58125
(72±7%) (Figure 4).
DISCUSSION
This pharmacological study conducted in healthy rats
provides evidence previously unreported to our knowledge
that cathodal CIV mainly relies on the release of PGI2,
endogenously produced through a COX-1-dependent me-
chanism that includes PGIS activation, and then acts on IP
receptors to relax the cutaneous microvessels (Figure 2),
whereas ACh-mediated vasodilation mainly relies on NO in
physiological conditions. This indicates that cathodal CIV
could be a valuable method to test the role in vascular
function of endogenous PGI2 in healthy skin.
We report here that a galvanic current application induces
a cutaneous vasodilation in rats, as previously reported in
humans (Durand et al., 2002a; Tartas et al., 2005b). Although
CIV exists at both electrodes (anode and cathode), we
showed in rats that the amplitude of CIV is almost three
times greater at the cathode (77%) than at the anode (26%)
for the same charge, as previously shown in humans (Morris
and Shore, 1996; Berliner, 1997; Durand et al., 2002a).
Moreover CIV was significantly reduced by aspirin, whereas
Current application
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Skin
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Figure 2. Proposed signaling pathway for cathodal CIV in cutaneous
microcirculation in healthy rats. In response to cathodal current stimulation
applied to the skin, COX-1 is likely to provide the substrate for PGIS, which
catalyzes the conversion of PGH2 to the potent vasodilator PGI2, which then
activates IP receptors present on SM, leading to CIV. The drugs that were used
and the measurements of 6-ketoPGF1a are also indicated. AA, arachidonic
acid; CIV, current-induced vasodilation; COX, cyclooxygenase;
IP, prostacyclin receptor; PGH2; prostaglandin H synthase 2; PGI2,
prostacyclin; PGIS, prostacyclin synthase; SM, smooth muscle.
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Figure 3. PGI2 release in the skin samples in response to cathodal current
stimulation. Mean±SEM of 6-ketoPGF1a levels in the skin samples in
response to cathodal current stimulation (240 seconds, 100 mA) in control rats
(n¼6) and in rats treated with a non-specific inhibitor of COX (aspirin, n¼ 6),
a specific inhibitor of COX-1 (SC560, n¼ 6), a specific inhibitor of PGIS
(U-51605, n¼6), a specific inhibitor of COX-2 (SC58125, n¼ 6), and a
specific inhibitor of NOS (NG-nitro-L-arginine, n¼ 6). ***Po0.001 versus
controls. C, control rats; COX, cyclooxygenase; PGI2, prostacyclin; PGIS,
prostacyclin synthase.
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Figure 4. COX and NOS involvement in the cutaneous response to
acetylcholine. Mean±SEM of vasodilation in response to the iontophoretic
delivery of acetylcholine (2%) in control rats (n¼ 10) and in rats treated with a
non-specific inhibitor of COX (aspirin, n¼ 10), a specific inhibitor of COX-1
(SC560, n¼ 10), a specific inhibitor of COX-2 (SC58125, n¼ 10), a specific
inhibitor of NOS (NG-nitro-L-arginine, n¼ 10), and combined COX and NOS
inhibitors (n¼5). ***Po0.001 versus controls. Ach, acetylcholine; C, control
rat; COX, cyclooxygenase; NOS, nitric oxide synthase.
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it remained unchanged after specific COX-2 inhibition in rats,
as we previously reported in healthy humans (Durand et al.,
2002a, b, c, 2003; Tartas et al., 2005a, b; Rousseau et al.,
2008). Therefore, on the basis of these observations, it seems
that cathodal CIV in anesthetized rats contains all the features
that were already known for human skin. It thus supports that
the rat is a reliable experimental model to further explore the
underlying mechanisms involved in cathodal CIV.
Aspirin and indomethacin (data not shown) decreased
cathodal CIV by almost 80%, confirming the major contribu-
tion of COX pathways, as previously reported in humans
(Durand et al., 2002a; Tartas et al., 2005b). In contrast, acute
NOS inhibition with LNNA did not modify CIV, showing that
NO is not involved in cathodal CIV in these healthy
conditions. Increasing evidence suggests that there is
considerable ‘‘cross talk’’ between NO and prostaglandins
biosynthetic pathways (Mollace et al., 2005). Consistent with
that view, arachidonic acid-induced PGI2 synthesis was
enhanced when NOS was inhibited, whereas COX inhibition
with indomethacin augmented NO synthesis in cultured
endothelial cells (Marcelin-Jimenez and Escalante, 2001).
This interrelationship could partially explain why cathodal
CIV tended to increase in the presence of NOS inhibition.
Similarly, the potential upregulation of NO under COX
inhibition is consistent with the fact that the remaining CIV in
the presence of aspirin was abolished by LNNA, showing that
NO contributed to cathodal CIV in the presence of COX
inhibition. The endothelium-derived hyperpolarizing factor
pathway associated with the hyperpolarization of both
endothelial and vascular smooth muscle cells also con-
tributes to endothelium-dependent relaxations. However,
because endothelium-derived hyperpolarizing factor is resis-
tant to NOS and COX inhibition, that pathway is not involved
in cathodal CIV in healthy skin, as dual inhibition NOS/COX
totally abolished it. Therefore, in the healthy skin of rats, the
cathodal CIV mainly relies on the COX pathway, with a
limited participation by NO when the COX pathway is
disrupted.
In contrast to cathodal CIV, ACh-mediated vasodilation
mainly relies on NO with a limited participation by PGI2 in
the healthy skin of rats. Indeed the vasodilation induced
by ACh delivery into the skin was decreased by almost
80% under NOS inhibition with LNNA, showing a major
contribution by NO, as previously reported in humans
(Warren, 1994). In contrast, ACh-mediated vasodilation in
this study was unchanged by COX inhibitors (aspirin, SC560,
SC58125), showing that COX is not involved in the ACh-
mediated vasodilation, as previously reported (Warren, 1994;
Morris and Shore, 1996; Rousseau et al., 2008). However,
contradictory results showed that the ACh-mediated vasodi-
lation was reduced under COX inhibition with aspirin or
unchanged under NOS inhibition in human skin (Khan et al.,
1997; Noon et al., 1998). In presence of aspirin, we showed
that the remaining ACh-mediated vasodilation was almost
abolished by LNNA, as previously reported in young adult
mice (Gaubert et al., 2007). Thus, although to a lesser extent
than for the cathodal CIV, the cross talk between endothelial
factors was also observed in the ACh-mediated vasodilation
in the healthy skin of rats. Accordingly, the combined
inhibition of NOS and COX produced an even greater
attenuation of ACh-induced vasodilation compared with
either NOS or COX inhibition in healthy humans (Kellogg
et al., 2005; Lenasi and Strucl, 2008). Therefore, in the
absence of blockers, ACh-mediated vasodilation mainly
reflects the vascular function of endogenous NO, whereas
cathodal CIV mainly reflects the vascular function of
endogenous of PGI2. These two tests would be thus
complementary to assess the endothelial function of the
healthy skin.
Similar to the effects of COX inhibition with aspirin, we
demonstrated that specific COX-1 inhibition with SC560
decreased by almost 80% cathodal CIV, whereas COX-2
inhibition with SC58125 did not changed it. This clearly
shows the major contribution to CIV to be the COX-1
pathway in healthy conditions. Accordingly, healthy skin was
characterized by constitutively expressed COX-1 at epithelial
sites constituting an essential prerequisite for skin repair
(Kampfer et al., 2003). In contrast, the inducible enzyme
COX-2, which is not involved in CIV, is absent or rarely
identified in healthy skin (Leong et al., 1996; Kampfer et al.,
2003) and was found to be gradually increased in the case of
skin damage induced by mechanical scratching (Sugimoto
et al., 2006). Indeed COX-2 mainly contributes to inflamma-
tion and granulation after tissue injury (Mantyh et al., 2002;
Kampfer et al., 2003), although it is constitutively expressed
in large-vessel endothelial cells as a laminar shear-inducible
gene (Topper et al., 1996). In addition, we demonstrated that
PGIS inhibition with U-51605 also reduced cathodal CIV by
about 80%, showing that PGIS is a major contributor to CIV.
In agreement with these results, COX-1 but not COX-2
colocalizes with PGIS in endothelial cells (Liou et al., 2000).
The reduction in CIV after IP blockade with CAY10441 was
comparable with that following COX-1 and PGIS inhibition,
suggesting that cathodal CIV is mainly through the activation
of IP receptors. Therefore, through using pharmacological
drugs that are not currently available in humans, our present
findings showed that the COX-1/PGIS/IP pathway is impor-
tantly involved in cathodal CIV in the healthy skin of rats.
Other than in the context of inflammation, the present
findings demonstrated that cathodal current stimulation
induced a significant increase in the concentration of
6-ketoPGF1a in the skin at the stimulated site in untreated
healthy rats, reflecting an endogenous production of PGI2
that to our knowledge is previously unreported. This increase
in 6-ketoPGF1a concentration accompanying current
application was not observed after COX, COX-1, or PGIS
inhibition, demonstrating that the capacity of the cutaneous
microvessels to generate PGI2 in response to non-noxious
current application relies mainly on the COX-1/PGIS path-
way in the healthy skin of rats. In contrast, the 6-ketoPGF1a
concentration accompanying current application was in-
creased (in the same proportions as in controls) in the
presence of COX-2 and NOS inhibition, showing that neither
COX-2 nor NOS is a major contributor to the endogenous
production of PGI2 induced by cathodal current stimulation.
Cathodal CIV and the increase of 6-ketoPGF1a levels were
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observed in the untreated rats and under COX-2 and NOS
inhibition, whereas a large attenuation of cathodal CIV and a
lack of increase of 6-ketoPGF1a levels were observed under
COX, COX-1, and PGIS inhibition. The cutaneous vasodila-
tion in response to cathodal current stimulation was thus
related to a significant increase of 6-ketoPGF1a levels in the
skin samples, supporting the conclusion that cathodal CIV
mainly relies on the endogenous production of PGI2 in the
healthy skin of rats. An even greater increase of 6-ketoPGF1a
levels in the skin samples was found in response to
arachidonic acid, showing a large production of PGI2 related
to an increase of 115% in the levels of cyclic AMP, the
second messenger for PGI2, without changing the basal cyclic
guanosine monophosphate levels in the healthy skin of rats
(data not shown). These findings are in agreement with the
fact that PGI2 is the predominant COX metabolite made by
healthy endothelial cells. However, we cannot totally
exclude the participation of other vasodilator prostaglandins
(PGE2, PGD2, and PGF2a) in cathodal CIV.
In conclusion, COX-1 and PGIS inhibition strongly
decreased cathodal CIV and prevented the endogenous
production of PGI2 in the healthy skin of rats, in contrast to
COX-2 and NOS inhibition. Rather than actual involvement
of NOS in cathodal CIV in healthy skin, its contribution was
restricted to conditions when COX was inhibited. Therefore,
in response to cathodal current stimulation applied to the
healthy skin, COX-1 is likely to provide the substrate for
PGIS, which catalyzes the conversion of prostaglandin H
synthase 2 to the potent vasodilator PGI2, which in turn
activates IP receptors present on smooth muscle, leading to
cathodal CIV in rats, with only a limited participation by NO.
In contrast, in response to cutaneous delivery of ACh, NOS
provides NO to relax vascular smooth muscle, with a limited
participation by PGI2 in the healthy skin of rats. This study
indicates that cathodal current stimulation could be a
valuable method to assess in vivo the vascular function of
endogenous PGI2, indicating the bioavailability of PGI2 in the
healthy skin in a non-invasive and easily accessible manner,
whereas ACh would be a better test of the vascular function
of endogenous NO. Regarding the crucial role had by PGI2
against ischemia and thrombosis, there is a considerable
relevance of galvanic stimulation with many potential
applications in both research and clinical practice in a
preventive approach. Whether a possible link exists between
altered CIV, indicating an impairment of the PGIS/PGI2/IP
pathway at the cutaneous level, and the complications
attributed to PGI2 deficiency and/or PGI2/TxA2 balance
disturbances deserves further studies.
MATERIALS AND METHODS
Animal instrumentation
Experiments were performed in male Wistar rats weighing 200–400 g
and aged from 7 to 10 weeks. Before the experiments, animals had
free access to standard laboratory food and water. Animals were
housed in a regulated environment with a constant ambient
temperature of 24 1C. Procedures for the maintenance and use of
the experimental rats were carried out in accordance with the
principles of French legislation and the experiments were approved
by the ethics committee for animal experimentation of the University
of Lyon, France.
The hair was removed from the skin of the animals with a
depilatory lotion to present hairless areas on the thighs area for
cutaneous blood flow measurements and local current application.
This depilation was performed 2 days before the experiments to
avoid any influence of skin irritation at the time of the studies.
For the experiments, animals were lightly anaesthetized with
Nesdonal (50mg kg1 body weight, intraperitoneal). One femoral
vein was cannulated with polyethylene catheters (PE 10) for
intravenous (i.v.) administration of drugs. The rats were then placed
in the prone position in an incubator warmed to maintain a stable
cutaneous temperature (35.5±0.1 1C) measured using a thermo-
couple (Physitemp BAT-12, Physitemp instruments, Clifton, NJ)
placed near the current application site. Systolic arterial blood
pressure was measured before the application of current and at the
end of the experiment using a pressure transducer placed on the tail
(XBP-1000, Kent Scientific, Torrington, CT).
Assessment of cathodal CIV
The effect on the cutaneous blood flow in response to cathodal
current application of 100mA, through deionised water, was
performed on the skin of the thigh in anesthetized rats using an
iontophoretic probe that was adapted to hold a laser Doppler probe
(PF 4001 Master, Periflux, Perimed, Sweden). The laser Doppler
signal expressed in arbitrary units was digitized with a 200Hz
sampling frequency using a computerized acquisition system (MP
100, Biopac System, CA).
Data collection started with a 1-minute control period before the
cathodal stimulation and was continued for 20minutes.
A preliminary study was performed to determine the minimal
duration of current application that would induce the maximal stable
amplitude of cathodal CIV in rats. We thus tested the effects of
different durations of current application on cutaneous blood flow:
0 seconds (n¼ 10), 120 seconds (n¼ 10), 240 seconds (n¼ 10), and
360 seconds (n¼ 10). The amplitude of CIV increased with increas-
ing duration of current application and reached its maximal
amplitude after 240 seconds application. As CIV amplitude was
not further increased following a longer duration (Figure 5a), we
applied the cathodal current for 240 seconds to study the underlying
mechanisms of CIV in all protocols. We also ensured in a
preliminary study that cathodal CIV was greater than anodal CIV
after the 240 seconds current application (77±7% vs. 26±6%,
Po0.001, Figure 5b).
Measurement of 6-ketoPGF1a levels
The release of PGI2 was determined in skin sample (62±13mg)
taken using a 8-mm diameter punch biopsy in the following
conditions: basal (no current stimulation, n¼ 6), at the site of
cathodal current application (240 seconds, 100 mA), and at the site of
arachidonic acid injection (10mM, 0.1ml, subcutaneous, n¼ 6) in
anesthetized untreated rats. Skin samples were also taken from the
site of cathodal current application in rats treated with aspirin
(50mg kg1, i.v., n¼ 6), SC560 (2.5mg kg1, i.v., n¼ 6), U-51605
(0.6mg kg1, i.v., n¼ 6), SC58125 (5mg kg1, i.v., n¼ 6), and
LNNA (20mg kg1, i.v, n¼ 6). Each skin sample was snap frozen in
liquid nitrogen and kept at 80 1C. Each frozen skin sample was
placed in a glass tube with 250 ml of phosphate-buffered saline
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solution containing 100mgml1 of indomethacin to inhibit further
synthesis of prostanoids. The tube was placed on dry ice and the
tissue was homogenized in a Potter. The resulting insoluble protein
was removed by centrifugation (2,000 g for 10minutes) at 4 1C.
The amounts of 6-ketoPGF1a present in the extracts were
measured as an estimate of PGI2 using a competitive enzyme
immunoassay kit (Cayman Chemical, Ann Arbor, MI). Absorbance of
the samples and of the corresponding standard curve were read on a
PowerWave XS microplate spectrophotometer (Bio-Tek Instruments,
Winooski, VT) at 410 nm. The lower limit of detection was 6 pgml1
for 6-ketoPGF1a.
COX/PGIS/IP involvement in cathodal CIV
A pharmacological approach was used to identify the involvement of
the underlying signaling pathway in CIV. A cathodal current
(240 seconds, 100 mA) was applied to the skin in rats treated
with a non-specific COX-1/COX-2 inhibitor (aspirin, 50mg kg1,
i.v., n¼ 10), a specific inhibitor of COX-1 (SC560, 2.5mg kg1, i.v.,
n¼ 10), a specific inhibitor of COX-2 (SC58125, 5mg kg1,
i.v., n¼ 10), a specific inhibitor of PGIS (U-51605, 0.6mg kg1,
i.v., n¼ 10), or a specific antagonist of IP receptor (CAY10441,
6mg kg1, i.v., n¼ 10). The treated rats were compared with control
rats that received the same volume of the corresponding vehicle:
DMSO (i.v., n¼ 10) for aspirin; SC560, SC58125, and CAY10441;
and methylacetate (i.v., n¼ 10) for U-51605.
NOS involvement in cathodal CIV
In addition to PGI2, the potent vasodilator NO also counteracts
leukocyte adhesion to the endothelium (Kubes et al., 1991; Gauthier
et al., 1995) and platelet aggregation (de Graaf et al., 1992). To
examine the NOS involvement in CIV, a cathodal current
(240 seconds, 100mA) was applied to the skin in rats treated with
an inhibitor of the constitutive NOS (LNNA, 20mg kg1, i.v.)
(Tabrizi-Fard and Fung, 1996) alone (only LNNA, n¼ 10) and
in the presence of aspirin (aspirinþ LNNA, n¼ 5). The saline
control rats (n¼ 10) received the same volume of saline (i.v.) as
the treated rats.
NOS and COX involvement in the ACh-mediated vasodilation
To examine the endothelium-dependent endogenous NO vas-
dilator capacities of the cutaneous microvessels, cutaneous blood
flow was measured in response to anodal iontophoretic delivery
(100mA; 20 seconds) of ACh (2% dissolved in deionised water)
in rats treated with a non-specific COX inhibitor (aspirin,
50mg kg1, i.v., n¼ 10), a specific inhibitor of COX-1 (SC560,
2.5mg kg1, i.v., n¼ 10), a specific inhibitor of COX-2 (SC58125,
5mg kg1, i.v., n¼ 10), and a NOS inhibitor (LNNA, 20mg kg1,
i.v.) alone (only LNNA, n¼ 10) and in combination with aspirin
(aspirinþ LNNA, n¼ 5). The control rats (n¼ 10) received the same
volume of saline as the treated rats.
Drugs
Aspirin, LNNA, ACh, arachidonic acid, methylacetate, and DMSO
were purchased from Sigma (Saint Quentin Fallavier, France).
SC560, SC58125, U-51605, and CAY10441 was purchased form
Cayman Chemical (Ann Arbor, MI). Cathodal current stimulation
and delivery of ACh were assessed 30minutes after the injection of
aspirin, CAY10441 or DMSO; 15minutes after SC560, SC58125,
LNNA, or saline; and 60minutes after U-51605 or methylacetate. All
of these drugs have been used to produce the optimal desired
pharmacological effect according to previous protocols (Bayorh
et al., 2002; von der Weid et al., 2004; Atar et al., 2006; Yamada
et al., 2008), as well as in preliminary studies from our laboratory
(data not shown).
Data analysis
The signals from the laser Doppler probe were averaged every
10 seconds to reduce instantaneous variability owing to vasomotion.
Results are expressed as means±SEM. Baseline values were
calculated as the average over the 1-minute baseline period before
the current application or ACh delivery. Vasodilation was then
reported as the maximal percentage increase in the cutaneous blood
flow above the baseline in response to cathodal current stimulation
(CIV) or ACh delivery.
Student’s paired t-test was used to evaluate the significance of
changes within a group. To determine the significance of results
between two groups, we used an unpaired Student t-test, whereas
we used an analysis of variance test followed by post hoc Dunett’s
test to compare more than two groups (rats receiving the vehicle as
controls). A two-tailed P-value o0.05 was regarded as statistically
significant.
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Figure 5. Effect of the cathodal current duration and polarities on current-
induced vasodilation amplitude. Mean±SEM of the maximal cutaneous
blood flow increase from baseline in response to an application of a cathodal
current of 100 mA for 0 seconds (n¼ 10), 120 seconds (n¼ 10), 240 seconds
(n¼10), and 360 seconds (n¼ 10) in anesthetized rats (a). **Po0.01 versus
application of cathodal current for 360 seconds. Mean±SEM of the maximal
cutaneous blood flow increase from baseline in response to an application of
cathodal (n¼ 10) and anodal (n¼ 10) currents of 100 mA for 240 seconds in
anesthetized rats (b). ***Po0.001 versus cathodal current.
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